Recent Updates
Recently added Catalysts
IDYA

IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

Thursday, April 15, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma

Full Press Release Details

IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma.
ShareAdd on Google
Tags: IDYA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 15, 2021

Biotech snapshot

Cash runway
$1243M liquidity · $29M/mo burn
~42 mo
Minimal dilution risk
Lead asset
IDE892Phase 1
NSCLC Adenocarcinoma →

Catalyst track record

+47%
best trade around IDYA's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for IDYA.

See every catalyst's timing & PoA →